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Abstract. 
 
The cadherins are a family of homophilic ad-
hesion molecules that play a vital role in the formation 
of cellular junctions and in tissue morphogenesis. Mem-
bers of the integrin family are also involved in cell to 
cell adhesion, but bind heterophilically to immunoglob-
ulin superfamily molecules such as intracellular adhe-
sion molecule (ICAM)–1, vascular cell adhesion mole-
cule (VCAM)–1, or mucosal addressin cell adhesion 
molecule (MadCAM)–1. Recently, an interaction be-
tween epithelial (E-) cadherin and the mucosal lym-
 
phocyte integrin, 
 
a
 
E
 
b
 
7
 
, has been proposed. Here, we 
demonstrate that a human E-cadherin–Fc fusion pro-
tein binds directly to soluble recombinant 
 
a
 
E
 
b
 
7
 
, and to 
 
a
 
E
 
b
 
7
 
 solubilized from intraepithelial T lymphocytes. 
Furthermore, intraepithelial lymphocytes or trans-
fected JY
 
9
 
 cells expressing the 
 
a
 
E
 
b
 
7
 
 integrin adhere 
strongly to purified E-cadherin–Fc coated on plastic, 
and the adhesion can be inhibited by antibodies to 
 
a
 
E
 
b
 
7
 
 
or E-cadherin.
The binding of 
 
a
 
E
 
b
 
7
 
 integrin to cadherins is selective 
since cell adhesion to P-cadherin–Fc through 
 
a
 
E
 
b
 
7
 
 re-
quires 
 
.
 
100-fold more fusion protein than to E-cad-
herin–Fc. Although the structure of the 
 
a
 
E
 
-chain is 
unique among integrins, the
 
 
 
avidity of 
 
a
 
E
 
b
 
7
 
 for E-cad-
herin can be regulated by divalent cations or phorbol 
myristate acetate. Cross-linking of the T cell receptor 
complex on intraepithelial lymphocytes increases the 
avidity of 
 
a
 
E
 
b
 
7
 
 for E-cadherin, and may provide a 
mechanism for the adherence and activation of lym-
phocytes within the epithelium in the presence of spe-
cific foreign antigen. Thus, despite its dissimilarity to 
known integrin ligands, the specific molecular interac-
tion demonstrated here indicates that E-cadherin is a 
direct counter receptor for the 
 
a
 
E
 
b
 
7
 
 integrin.
 
T
 
he
 
 cadherins constitute a family of cell surface ad-
hesion molecules that are involved in calcium-
dependent homophilic cell to cell adhesion (Takei-
chi, 1990). The best studied human cadherins, E-, P-, N-,
and VE-cadherin, have a restricted tissue distribution: E-
and P-cadherin are expressed in epithelial tissues (Nose
and Takeichi, 1986; Shimoyama et al., 1989
 
a
 
), N-cadherin
is found mainly on neural cells (Hatta et al., 1987), and
VE-cadherin is found on vascular endothelium (Lampugn-
ani et al., 1992). Homophilic binding between cadherins on
adjacent cells is vital for the maintenance of strong cell to
cell adhesion in these tissues. For example, E-cadherin is
required for the formation of adherens junctions between
mature epithelial cells (Boller et al., 1985; Gumbiner et al.,
1988) and is involved in Langerhans cell adhesion to kera-
tinocytes (Tang et al., 1993), and VE-cadherin is needed
for the maintenance of lateral association between endo-
thelial cells (Lampugnani et al., 1992). During development
cadherins are critically involved in the cell sorting required
for tissue morphogenesis (Takeichi, 1995), and loss of
E-cadherin function contributes to the metastasis of a vari-
ety of carcinomas (Ben-Ze’ev, 1997). The extracellular re-
gions of mature mammalian cadherins are comprised five
“CAD” modules of 
 
z
 
110 amino acids. Crystallographic
and biochemical studies indicate that cadherins probably
form dimers on the cell surface (Shapiro et al., 1995; Nagar
et al., 1996), and that interaction with dimeric cadherins on
opposing cell surfaces can lead to the formation of “zip-
per-like” cell junctions (Shapiro et al., 1995; Tomschy et
al., 1996).
The integrins are a second family of transmembrane ad-
hesion molecules that are involved in both cell to cell and
cell to matrix interactions. At least 15 
 
a
 
 chains associate
with 8 
 
b
 
 chains to form a large number of heterodimeric
integrins that can be classified into several major subfami-
lies based on their shared use of a particular 
 
b
 
 chain
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(Hynes, 1992). Members of three such subfamilies, the 
 
b
 
1
 
,
 
b
 
2
 
, and 
 
b
 
7
 
 integrins, are commonly found on leukocytes.
The expression of 
 
b
 
1
 
 integrins is widespread (for example,
 
a
 
5
 
b
 
1
 
, CD49e/CD29, is found on T cells, granulocytes,
platelets, fibroblasts, endothelium, and epithelium), whereas
the 
 
b
 
2
 
 and 
 
b
 
7
 
 integrins have a restricted pattern of expres-
sion. For example, 
 
a
 
L
 
b
 
2
 
 (CD11a/CD18) is expressed on
most lymphocytes and many myeloid cells but not on
other cell types, and 
 
a
 
E
 
b
 
7
 
 (CD103/unclustered) is found
on 
 
.
 
95% of intestinal intraepithelial lymphocytes (iIEL)
 
1
 
and on other mucosal T cells, macrophages, and mast cells,
but on only 2% of peripheral blood lymphocytes (Cerf-
Bensussan et al., 1987; Smith et al., 1994; Tiisala et al.,
1995). The major ligands of the integrins fall into two cate-
gories: cell surface molecules that are members of the im-
munoglobulin superfamily (such as vascular cell adhesion
molecule [VCAM]–1, intracellular adhesion molecule
[ICAM]–1, 2, 3, and mucosal addressin cell adhesion mole-
cule [MadCAM]–1) and a variety of large extracellular
proteins (such as fibronectin, vitronectin, fibrinogen, and
complement component iC3b; Hynes, 1992). A common
feature of both groups is the presence of exposed acidic
amino acids crucial for integrin binding (Bergelson and
Hemler, 1995). Many integrins exist in states of low or
high avidity for their ligands, and these states can be regu-
lated from within the cell (Hynes, 1992). For example, the
avidity of 
 
a
 
L
 
b
 
2
 
 on resting T cells can be increased by stim-
ulation through the T cell receptor (TCR) with anti–CD3
mAbs (Dustin and Springer, 1989; van Kooyk et al., 1989).
Recently, we reported that E-cadherin on human epi-
thelial cells may be a ligand for the mucosal lymphocyte
integrin, 
 
a
 
E
 
b
 
7
 
, and a similar interaction has been sug-
gested in the mouse (Cepek et al., 1994; Karecla et al.,
1995). mAbs to E-cadherin or to 
 
a
 
E
 
b
 
7
 
 block IEL adher-
ence to epithelial cells, and transfection of cells with 
 
a
 
E
 
b
 
7
 
confers upon them the ability to adhere to cells transfected
with E-cadherin (Cepek et al., 1994). E-cadherin has been
defined extensively as a homophilic adhesion molecule,
and its sequence is not related to known cell surface or ex-
tracellular integrin ligands. Thus, the concept that 
 
a
 
E
 
b
 
7
 
and E-cadherin are counter receptors is at variance with
current knowledge of both integrin and cadherin interac-
tions. Moreover, as we and others have pointed out, the in-
direct methods used in the studies to date are insufficient
to conclusively demonstrate a direct physical interaction
between these two adhesion receptors (Cepek et al., 1994;
Erle, 1995; Karecla et al., 1995; Takeichi, 1995). For exam-
ple, it is clear that antibodies to one integrin (e.g., 
 
a
 
V
 
b
 
3
 
)
can cause specific transdominant inhibition of the function
of another integrin (e.g., 
 
a
 
5
 
b
 
1
 
; Blystone et al., 1995; Díaz-
González et al., 1996) or could result in steric hindrance of
an adjacent receptor. Furthermore, expression of an exog-
enous gene in a transfected cell can have profound effects
on the surface expression of a variety of other proteins
(Marks et al., 1996), and the transfection of constructs con-
taining integrin 
 
b
 
1 tails into fibroblasts alters the function
 
of endogenous integrins (LaFlamme et al., 1994). Such ef-
fects can lead to erroneous conclusions about the interac-
tions that are directly involved in adhesion.
Given that the interaction of 
 
a
 
E
 
b
 
7 
 
on intraepithelial lym-
phocytes with its receptor on epithelial cells is likely to be
crucial for the normal development, function, and/or re-
tention of lymphocytes in the epithelium (Cepek et al.,
1993; Erle, 1995), we sought to determine if 
 
a
 
E
 
b
 
7
 
 and
E-cadherin are directly interacting counter receptors. In
addition, we investigated whether this interaction is spe-
cific among cadherins and whether it can be regulated
through alterations in 
 
a
 
E
 
b
 
7
 
 avidity.
 
Materials and Methods
 
Materials
 
DNA manipulating enzymes were purchased from New England Biolabs
Inc. (Beverly, MA). Oligonucleotides were obtained from Oligotech (Bos-
ton, MA). Other chemicals were purchased from Sigma Chemical Co. (St.
Louis, MO). ICAM-1–Fc (the entire extracellular region of human
ICAM-1 fused to the hinge and Fc portion of human IgG1) was a gener-
ous gift of Dr. Lloyd Klickstein (Brigham and Women’s Hospital, Boston,
MA). Purified human IgG1 was obtained from Calbiochem-Novabiochem
Corp. (La Jolla, CA).
 
mAbs
 
The mAb used (all mouse IgG against human antigens) were as follows:
E4.6 (anti–E-cadherin, IgG1; Cepek et al., 1994), HECD-1 (anti–E-cad-
herin, IgG1; Shimoyama et al., 1989
 
b
 
), NCC-CAD299 (anti–P-cadherin,
IgG1; Shimoyama et al., 1989
 
b
 
), HML-1 (anti-
 
a
 
E
 
b
 
7
 
, IgG2a; Cerf-Bensus-
san et al., 1987), BerACT-8 (anti-
 
a
 
E
 
b
 
7
 
, IgG1; Kruschwitz et al., 1991),
 
a
 
E7-1 (anti-
 
a
 
E
 
b
 
7
 
, IgG2a; Russell et al., 1994), 
 
a
 
E7-2 (anti-
 
a
 
E
 
b
 
7
 
, IgG1;
Russell et al., 1994), 
 
a
 
E7-3 (anti-
 
a
 
E
 
b
 
7
 
, IgG1; Russell et al., 1994), D6.21
(anti-
 
a
 
L
 
b
 
2
 
, IgG1; Cepek et al., 1993), TS1/22 (anti-
 
a
 
L
 
b
 
2
 
, IgG1; Sanchez-
Madrid et al., 1982), TS1/18 (anti-
 
b
 
2
 
, IgG1; Sanchez-Madrid et al., 1983),
ACT-1 (anti-
 
a
 
4
 
b
 
7
 
, IgG1; Lazarovits et al., 1984), B5G10 (anti-
 
a
 
4
 
, IgG1;
Hemler et al., 1987), 4B4 (anti-
 
b
 
1
 
, IgG1; Morimoto et al., 1985), RR1/1
(anti–ICAM-1, IgG1; Rothlein et al., 1986), SPVT3b (anti-CD3
 
e
 
, IgG2a;
Spits et al., 1983), OKT4 (anti-CD4, IgG2b; obtained from American
Type Culture Collection [ATCC], Rockville, MD), OKT8 (anti-CD8
 
a
 
,
IgG2a; ATCC), W6/32 (anti-MHCI, IgG2a; Barnstable et al., 1978), TCR-
 
d
 
1
(anti–TCR-
 
d
 
, IgG1; Band et al., 1987), P3 (control IgG1; Kohler and Mil-
stein, 1975), RPC5.4 (control IgG2a; Mohit and Fan, 1971).
 
Cells
 
Human iIEL were isolated as previously described (Roberts et al., 1993;
Russell et al., 1996). The iIEL were stimulated with PHA-P (Difco Labo-
ratories Inc., Detroit, MI) and irradiated feeder cells (80% PBMC and
20% JY lymphoblastoid cells) in 2 nM IL-2, 4% (vol/vol) heat-inactivated
FBS (Hyclone Laboratories Inc., Logan, UT), 50 
 
m
 
M 2-mercaptoethanol,
and Yssel’s medium at 10% CO
 
2
 
 (Russell et al., 1996). The iIEL lines 496
and 194 were maintained by periodic restimulation as described and were
used in adhesion assays after 2–8 wk. At the time of assay, IEL496 was
100% CD3
 
1
 
, 90% CD81, 10% CD41, 95% aLb2
1 (MFI z 400), 97%
aEb7
1 (MFI z700), and IEL194 was 100% CD31, 60% CD81, 40% CD41,
95% aLb2
1 (MFI z500), 80% aEb7
1 (MFI z600) by FACS® analysis. Both
lines maintained expression of aEb7 without addition of exogenous TGF-b1.
A subline of the human B lymphoblastoid cell line, JY, that expresses
the a4b7 integrin (JY9), was kindly provided by Dr. Martin Hemler (Dana-
Farber Cancer Institute, Boston, MA; Chan et al., 1992) and was main-
tained in 10% (vol/vol) heat-inactivated FBS (Hyclone Laboratories Inc.),
RPMI-1640 (GIBCO BRL, Gaithersburg, MD) at 378C, and 5% CO2. Hu-
man embryonic kidney HEK293 cells (obtained from ATCC) were main-
tained in 10% (vol/vol) heat-inactivated FBS (Hyclone Laboratories Inc.)
and DME Medium (GIBCO BRL) at 378C in 10% CO2. COS-7 cells (ob-
tained from ATCC) were grown in 10% (vol/vol) NuSerum (Collabora-
tive Research, Inc., Waltham, MA), 10 mM Hepes, 2 mM L-glutamine,
and DMEM (GIBCO BRL) at 10% CO2. Human breast epithelial
16E6.A5 cells were maintained as described (Cepek et al., 1993).
1. Abbreviations used in this paper: ICAM, intracellular adhesion mole-
cule; iIEL, intestinal intraepithelial lymphocytes; MadCAM, mucosal ad-
dressin cell adhesion molecule; MFI, mean fluorescence intensity; PBL,
peripheral blood lymphocytes; TCR, T cell receptor; VCAM, vascular cell
adhesion molecule.Higgins et al. Direct Interaction of aEb7 Integrin and E-Cadherin 199
Construction of E- and P-Cadherin–Fc
Expression Vectors
E-cadherin–Fc. A double-stranded DNA adapter containing a 59 Ngo MI
cohesive end, the final five codons of the human E-cadherin extracellular
region, and a 39 XhoI cohesive end was produced by annealing the compli-
mentary oligonucleotides JON1 (59-CCGGCGTCTGTAGGAAGC-39)
and JON2 (59-TCGAGCTTCCTACAGACG-39). This adapter was then
ligated to the 39-end of an EcoRV–NgoMI fragment encoding the rest of
the extracellular region of human E-cadherin derived from the plasmid
pERF-1 (kindly provided by Dr. David Rimm, Yale University, New Ha-
ven, CT; Rimm and Morrow, 1994). After removal of excess adapters by
centrifugation through a Centricon-100 filter (Amicon Corp., Danvers,
MA), the resulting EcoRV–XhoI fragment was introduced inframe, up-
stream of coding for the hinge and Fc region of human IgG1 in a deriva-
tive of pCDM8 (pCDM8/Fc; Chen and Nelson, 1996) also cleaved with
EcoRV and XhoI. The sequence of the junctional region is shown in Fig. 1 a.
To confirm the integrity of the construct, the nucleotide sequence of the
junctional region of the E-cadherin–Fc construct was determined by dou-
ble-stranded sequencing using the Sequenase kit (United States Biochem-
ical Corp., Cleveland, OH) according to the manufacturer’s protocol. Fi-
nally, the E-cadherin–Fc cDNA was excised from pCDM8 using EcoRV
and NotI and ligated into the expression vector pCEP4 (Invitrogen Corp.,
Carlsbad, CA) cleaved with PvuII and NotI.
P-Cadherin–Fc. An adapter fragment encoding the final 93 codons of
the human P-cadherin extracellular region was generated by PCR from a
human P-cadherin cDNA in pBR322 (kindly provided by Dr. S. Hirohashi,
National Cancer Center Research Institute, Tokyo, Japan; Shimoyama et
al., 1989b) using the primers JON4 (59-GGCGTGCCACCTACCTTAT-
CAT-39) and JON5 (59-TTTTTTCTCGAGTCCAGGGCAGGTTTC-
GAC-39) and cloned plaque-forming unit (PFU) polymerase (Stratagene,
La Jolla, CA) according to the manufacturer’s recommendations, with 25
cycles of 948C 1 min/558C 1 min/728C 1 min. After digestion with BsaBI
and XhoI, this adapter was ligated to the 39-end of a HindIII–BsaBI frag-
ment encoding the rest of the extracellular region of human P-cadherin.
After digestion of the ligation products with HindIII and XhoI and purifi-
cation of the required fragment by Agarose gel electrophoresis and US-
Bioclean (United States Biochemical Corp.), the resulting HindIII–XhoI
fragment was introduced into pCDM8/Fc cleaved with HindIII and XhoI.
The sequence of the junctional region is indicated in the legend of Fig. 1 a.
After sequencing as described above, the P-cadherin–Fc cDNA was ex-
cised with HindIII and NotI, and inserted into pCEP4 cleaved with the
same enzymes.
DNA for transfections was prepared using a Maxi-prep kit (QIAGEN
Inc., Chatsworth, CA).
Construction of aE and b7 Expression Vectors
Full-Length aE. A full-length open reading frame encoding human aE was
generated from cDNA clones described previously (Shaw et al., 1994).
The final construct included the HindIII–NsiI fragment of clone 38, the
NsiI–BsaBI fragment of clone 2-54, the BsaBI–AccI fragment of clone 1-39A,
the AccI–BglII fragment of clone 2-54, and the BglII–XhoI fragment of
clone 3-15. The full-length cDNA was introduced into the XhoI site of
the expression vector pSRa-neo (Takebe et al., 1988) to produce pSRa-
neo/aE.
Truncated aE. PCR was used to introduce a stop codon and HindIII site
immediately upstream of the transmembrane region of human aE cDNA
(see Fig. 1 b). PCR with the primers 59-AAGAATGGCATTCAGT-
GAGC-39 and 59-GGGAAGGTTGATGATAGGCTAAGAATGGTAC-39
amplified a product that was subsequently cleaved with BglII and HindIII
to generate a 180-bp fragment from the end of the aE extracellular region.
This fragment was then introduced into the BglII site of the full-length aE
cDNA to generate an open reading frame for the entire extracellular por-
tion of human aE. After sequencing as described above, the truncated aE
cDNA was introduced in either the sense or antisense direction into the
HindIII site of the expression vector pAPRM8 (Wong and Farrell, 1991)
to produce pAPRM8/taEs and pAPRM8/taEas.
Truncated b7. A full-length human b7 cDNA was derived by ligation of
the XhoI–EcoRI fragment from a partial b7 cDNA (kindly provided by
Dr. G.W. Krissansen, University of Auckland, New Zealand; Yuan et al.,
1990) and the NotI–XhoI fragment of another partial b7 cDNA cloned
from an IEL cDNA library (Shaw et al., 1994). To introduce a stop codon
and EcoRI site immediately upstream of the transmembrane region of hu-
man b7 cDNA, PCR with the primers 59-TCGCTGCCAATGTGGAG-
TATG-39 and 59-GGGGAATTCACAATGGCCTACGTGTGGTCTGC-39
was carried out. The product obtained was subsequently cleaved with
BsmI and EcoRI to generate a 400-bp fragment from the end of the b7 ex-
tracellular region. This fragment was then introduced into the BsmI and
EcoRI sites of pBluescript containing the b7 cDNA to generate an open
reading frame for the entire extracellular portion of human b7 (see Fig. 1
b). After sequencing as described above, the truncated b7 cDNA was ex-
cised from pBluescript with EcoRI and introduced in either the sense or
antisense direction into the EcoRI site of the expression vector pAPRM8
to produce pAPRM8/tb7s and pAPRM8/tb7as.
Production of Cadherin–Fc Proteins
HEK293 cells (106 cells per 75-cm2 flask) were stably transfected with 25
mg plasmid DNA using the Mammalian transfection kit (Stratagene Inc.).
After growth for 24 h in nonselective medium the cells were transferred to
96-well tissue culture plates and incubated in selective medium containing
300 mg/ml hygromycin B. After 15 d, supernatants from wells containing
resistant colonies were assayed for fusion proteins by ELISA.
To produce the cadherin–Fc proteins, transfected cells were grown in
triple-layer 500-cm2 flasks (Nunc, Roskilde, Denmark) in 10% (vol/vol)
Ultralow Ig FBS (GIBCO BRL), 300 mg/ml hygromycin B, and DMEM.
After 5–10 d of culture, the medium was harvested and filtered through a
0.2-mm membrane. The E- and P-cadherin–Fc fusion proteins were then
purified on separate, previously unused GammaBind G–Sepharose col-
umns (Pharmacia Biotech Sverige, Uppsala, Sweden). The columns were
washed with TBS and 1 mM CaCl2, pH 7.4, and then eluted with 0.2 M gly-
cine and 1 mM CaCl2, pH 2.3. Fractions containing purified fusion pro-
teins were dialyzed into TBS and 1 mM CaCl2, pH 7.4 and then stored at
2208C. The purity of fusion protein was assessed by SDS-PAGE and
Coomassie blue staining, and the concentration was determined by Brad-
ford assay using BSA as a standard (Bio-Rad Labs., Hercules, CA).
Production of Soluble 35S-labeled Recombinant
aEb7 Integrin
Soluble recombinant aEb7 was produced by COS-7 cells after transient
transfection using DEAE-dextran (Coligan et al., 1994, Unit 10-14) with
the plasmids pAPRM8/taEs and pAPRM8/tb7s. Control transfections
were carried out with the antisense constructs pAPRM8/taEas and
pAPRM8/tb7as. After incubation for 48 h in complete medium, the cells
were washed once with PBS and then 1 mCi 35S-Express (Dupont-NEN,
Boston, MA) in 6 ml 10% (vol/vol), dialyzed FBS, 5% DMEM, 85% me-
thionine- and cysteine-free DMEM (GIBCO BRL), 10 mM Hepes, and 2
mM  L-glutamine was added. After incubation at 378C for 24 h, the
medium, containing labeled secreted proteins, was filtered through a 0.2-
mm membrane.
Generation of JY9-aE and JY9-Vector Cell Lines
To produce cells expressing cell surface aEb7, JY9 cells that express endog-
enous  b7 integrin chain were transfected by electroporation with 4 mg
pSRa-neo/aE or with the pSRa-neo vector alone as a control. Then trans-
fected cells were selected by culture in 0.5 mg/ml G418. To generate the
JY9-aE line, aEb7-expressing transfectants were isolated by positive selec-
tion with the anti-aEb7 mAb BerACT-8 on magnetic goat anti–mouse im-
munoglobulin dynabeads according to the manufacturer’s recommenda-
tions (Dynal A.S., Oslo, Norway) and by flow cytometric sorting. FACS®
was carried out as previously described (Parker et al., 1990). The clone
J6.7 was finally isolated by limiting dilution. The aEb7 expressed on JY9-
aE cells was indistinguishable from that on IEL when immunoprecipitated
from 125I surface-labeled cells with the anti–aEb7 mAb, HML-1 (not shown).
Adhesion Assays
Unless otherwise stated, the wells of Linbro 96-well microtiter plates (ICN
Flow Laboratories, Horsham, MA) were coated with human IgG1 Fc-con-
taining proteins in 50 ml/well TBS and 1 mM CaCl2, pH 7.4, for 18 h at 48C.
The wells were subsequently washed twice with 20 mM Hepes, 137 mM
NaCl, and 3 mM KCl, pH 7.4 (HBS), with 1 mM CaCl2, and was then
blocked with 1% BSA (Calbiochem-Novabiochem Corp.), HBS, and 1 mM
CaCl2 for 2 h at room temperature. In assays in which the effects of diva-
lent cations were assessed, coating and blocking was carried out in HBS
and 10 mM EDTA. In assays in which adhesion to P- and E-cadherin–Fc
was compared, the wells were coated with 1 mg/well goat anti–human IgGThe Journal of Cell Biology, Volume 140, 1998 200
polyclonal antibody (Zymed, San Francisco, CA) in 100 ml TBS, pH 7.4,
and blocked as described above before addition of Fc fusion proteins.
IEL or transfected JY9 cells were labeled with BCECF-AM (Molecular
Probes, Eugene, OR) as previously described (Cepek et al., 1993). During
labeling of JY9 cells, 10% (vol/vol) heat-inactivated normal human serum
was included to block Fc receptors. Adhesion assays were carried out in
0.1% BSA and HBS with combinations of MnCl2, MgCl2, CaCl2, or 1 mM
EGTA, as indicated (see text). In antibody blocking experiments, cells or
wells were preincubated with mAbs for 10 min at 48C as described in the
text. For cell activation experiments, cells were preincubated with anti-
bodies or 50 ng/ml PMA at 48C for 15 min. Adhesion assays were carried
out as described previously (Cepek et al., 1993) with the following modifi-
cations. Labeled cells were brought into contact with the microtiter plate
wells by centrifugation at 60 g for 2 min (IEL) or 1 min (JY9). After incu-
bation at 378C for 10 min, nonadherent cells were removed by washing
with 1 mM MnCl2, 1 mM MgCl2, 1 mM CaCl2, and HBS at 378C unless the
effect of divalent cations was being assessed, in which case HBS alone was
used. Since in these assays the fluorescence of input cells was quenched to
some degree by the presence of adhesion buffer, but the percent bound
was determined after removing the buffer, some apparent readings of
.100% are obtained.
Homophilic adhesion assays were carried out as described above with
the following modifications. 16E6.A5 cells were released from culture
dishes using 0.02% (wt/vol) trypsin, 2 mM CaCl2, and HBS to minimize
proteolysis of cadherins. After adding 2 vol of 0.04% (wt/vol) soy bean
trypsin inhibitor, HBS, and washing twice with HBS, the cells were resus-
pended in 0.1% BSA, HBS, and 1 mM CaCl2 and allowed to settle onto
the microtiter plate wells for 10 min at 48C. After incubation at 378C for 30
min, and washing twice with HBS and 1 mM CaCl2, the percentage of
bound cells was determined using a fluorogenic assay of endogenous cel-
lular phosphatase activity (Tolosa and Shaw, 1996).
Surface Labeling of iIEL with 125I
Cultured iIEL (4 3 107) were isolated by centrifugation on Ficoll-Paque
(Pharmacia Biotech Sverige) and subjected to cell surface labeling with
2 mCi Na125I (Dupont-NEN) using the lactoperoxidase method (Coligan
et al., 1994, Unit 8-11). The labeled cells were then lysed in 0.5% Triton
X-100, TBS, and 4 mM iodoacetamide, 1 mM phenylmethylsulfonyl fluo-
ride for 4 h at 48C. Insoluble material was removed by centrifugation at
12,000 g for 20 min.
Immunoadsorption
Batches of 125I-labeled IEL lysate or 35S-labeled transfected COS-7 me-
dium were supplemented divalent cations (see text) and precleared twice
with 0.4% (vol/vol) normal rabbit serum, 1.5% (vol/vol) protein A–Sepharose
(Pharmacia), and 1.5% (wt/vol) Pansorbin (Calbiochem-Novabiochem
Corp.) for a total of 24 h at 48C. Subsequently, aliquots were incubated
with mouse mAbs or human IgG1 Fc-containing proteins for 3 h at 48C.
Then, 10 ml protein A–Sepharose resin was added to each tube, and the
incubation at 48C was continued for a further 3 h. For immunoprecipita-
tions using mouse IgG1 mAbs, protein A–Sepharose precoated with rab-
bit anti–mouse immunoglobulin polyclonal antibody (Cappel, West Ches-
ter, PA) was used. Then the immobilized complexes were washed six
times with TBS containing the same concentration of divalent cations used
during the adsorption steps. For immunoadsorption from IEL lysates, 0.1%
Triton X-100 was also present during washing. Proteins bound to the resin
were eluted by boiling in 3% (wt/vol) SDS, 10% (vol/vol) glycerol, 50%
(wt/vol) urea, and 60 mM Tris, pH 7, before analysis by SDS-PAGE.
SDS-PAGE
SDS-PAGE on 7.5% (wt/vol) polyacrylamide gels (Protogel; National Di-
agnostics, Atlanta, GA) was carried out as described (Coligan et al., 1994,
Unit 8-4). Samples were reduced by the inclusion of 25 mM dithiothreitol.
Radiolabeled proteins were visualized by autoradiography using Biomax
MR and MS film (Kodak, Rochester, NY) and quantitated using phosphor-
imaging and the ImageQuant package (Molecular Dynamics Inc., Sunny-
vale, CA).
Statistical Analysis
P values testing the hypothesis that two populations had equal means
were calculated using a two-tailed Welch t test (which assumes the popu-
lations follow a normal distribution, but not that they have equal vari-
ance). Also, a nonparametric two-tailed Mann-Whitney test (which does
not assume normal distributions) was used to test whether the population
medians were equal. Calculations were carried out using the Instat pack-
age (Graphpad Software, San Diego, CA).
Results
Production of Human E- and P-cadherin–Fc
Fusion Proteins
Constructs encoding the extracellular portion of either hu-
man E-cadherin or P-cadherin were linked in frame to a
construct encoding the Fc region of human IgG1 (includ-
ing the hinge, CH2, and CH3 domains). Transfection of
HEK293 cells and selection with hygromycin B led to the
generation of stable lines expressing soluble E-cadherin–
Fc or P-cadherin–Fc fusion proteins. The cadherin–Fc fu-
sion proteins were expected to be dimeric due to the pres-
Figure 1. Structure of soluble recombinant E-cadherin–Fc and
truncated aEb7. (a) Structure of the human E-cadherin–Fc fusion
protein. The sequence of the extracellular juxtamembrane region
of wild-type E-cadherin and the alterations resulting from fusion
with the human Fc region are shown. Regions corresponding to
the Fc portion are shown in bold. The corresponding sequences
in P-cadherin, tgc cct gga ccc tgg aaa (encoding CPGPWK), be-
come tgc cct gga ctc gag ctc (encoding CPGLEL) in the P-cad-
herin–Fc fusion protein. (b) Structure of soluble truncated aEb7.
In the aE chain, the EF hand–like repeats are labeled I to VII, the
extra “X” domain is shown in black, and the A domain in grey. In
the b7 chain, the b integrin conserved region that may resemble
an A domain (Lee et al., 1995) is shown in grey, and the cysteine-
rich repeats are hatched. The transmembrane and cytoplasmic re-
gions that were removed from each chain are shown as dotted
lines. The change made in the cDNA sequence of each chain to
introduce a stop codon immediately before the transmembrane
region is shown in bold.Higgins et al. Direct Interaction of aEb7 Integrin and E-Cadherin 201
ence of disulfide bonds in the Fc region (Fig. 1 a), possibly
similar to cadherin dimers on the cell surface (Shapiro et
al., 1995; Nagar et al., 1996).
After purification on protein G–Sepharose, SDS-PAGE
in reducing conditions revealed the presence of proteins of
the expected size for both E- and P-cadherin–Fc mono-
mers (z120 kD, Fig. 2). Minor species of 135 or 130 kD
were also present in preparations of the E- and P-cadherin
fusion proteins, respectively. Since cadherins are synthe-
sized as proproteins and the sizes of these bands match
those predicted for the immature forms, it is likely that a
small proportion of partially processed procadherin is
present in each case. In nonreducing conditions both fu-
sion proteins migrate at z240 kD (Fig. 2) as expected for
dimeric fusion proteins linked through disulfide bonds in
the hinge of the Fc region. A small proportion of mono-
meric cadherin fusion protein is also present in each case.
In an ELISA, E-cadherin–Fc but not P-cadherin–Fc is
recognized by the antihuman E-cadherin mAb E4.6, and
P-cadherin–Fc but not E-cadherin–Fc is recognized by the
antihuman P-cadherin mAb NCC-CAD299, further con-
firming the identity of the two recombinant products (not
shown).
E-Cadherin–Fc Supports Adhesion of IEL
Cell surface E-cadherin has been proposed to be a ligand
for the IEL integrin aEb7 (Cepek et al., 1994; Karecla et
al., 1995). To test the capacity of the cadherin–Fc fusions
to support adhesion of IEL, we immobilized the proteins
via antihuman IgG antibody on polystyrene microtiter
plate wells. Binding of IEL to wells coated with subnano-
gram quantities of E-cadherin–Fc could be detected in the
presence of 1 mM MnCl2, 1 mM MgCl2, and 1 mM CaCl2
(Fig. 3 a). At 1 ng/well, z40% of the IEL adhered, and
maximal adhesion occurred at 10 ng/well of E-cadherin–
Fc. Thus, a dose-dependent adhesion of IEL to the E-cad-
herin fusion protein was clear. Indeed, for IEL expressing
similar levels of aEb7 and aLb2, adhesion to human E-cad-
herin–Fc was similar or greater than that seen to human
ICAM-1–Fc (data not shown and see Fig. 3 b). In contrast,
adhesion to P-cadherin–Fc required .100-fold more fu-
sion protein and did not reach 100% at any coating con-
centration. 40% adhesion was seen to P-cadherin–Fc at
500 ng/well. No adhesion could be detected to wells coated
with 500 ng/well human IgG1 (Fig. 3 a).
Adhesion of PHA-activated peripheral blood lympho-
cytes (PBL) to E-cadherin–Fc could not be detected (data
not shown). This is consistent with the fact that only 2– 5%
of PBL express aEb7 (Cerf-Bensussan et al., 1987). The E-
and P-cadherin–Fc proteins support similar levels of adhe-
sion of 16E6.A5 epithelial cells (Cepek et al., 1993) that
express similar levels of E- and P-cadherin, suggesting that
both fusion proteins are equally able to support cadherin-
mediated homophilic adhesion (Fig. 3 c).
Antibodies to aEb7 and E-Cadherin Block IEL 
Adhesion to E-Cadherin–Fc
To determine if lymphocyte aEb7 was responsible for ad-
hesion of IEL to E-cadherin–Fc, we attempted to block
the interaction with mAbs to human lymphocyte surface
integrins. The binding of IEL to E-cadherin–Fc coated di-
rectly on plastic was completely blocked by anti–aEb7
mAbs HML-1, BerACT8, aE7-1, and aE7-2 and by the
anti–E-cadherin mAb E4.6, while adhesion to ICAM-1–Fc
was not affected (Fig. 3 b and data not shown). In contrast,
the anti-b2 integrin mAb, TS1/18, the anti–aLb2 mAbs,
TS1/22 and D6.21, and the anti–ICAM-1 mAb RR1/1 all
prevented IEL adhesion to ICAM-1–Fc, but not to E-cad-
herin–Fc. The anti-b1 integrin mAb, 4B4, blocked adhe-
sion of IEL to human fibronectin (not shown) but not to
E-cadherin–Fc or ICAM-1–Fc. A blocking mAb to a4b7
(ACT-1) also did not inhibit IEL adhesion to E-cadherin–
Fc or ICAM-1–Fc (Fig. 3 b). Adhesion of IEL to P-cad-
herin–Fc was also completely blocked by the anti–aEb7
mAb, aE7-2, but was unaffected by the anti–aLb2 mAb,
D6.21 (data not shown). Thus, adhesion of IEL to E- or
P-cadherin–Fc involves aEb7, and adhesion to ICAM-1–Fc
involves aLb2.
JY Cells Transfected with aE Adhere to E-Cadherin–Fc
To confirm that expression of exogenous aEb7 would con-
fer upon a cell the ability to adhere to E-cadherin–Fc, ad-
hesion assays were performed with JY9 cells transfected
with a full-length human aE-encoding cDNA construct.
JY9 cells, or JY9 cells transfected with vector only (JY9-
vector), expressed the a4b7 integrin, very little b1 integrin,
but no aEb7 by FACS®. JY9 transfected with aE (JY9-aE)
had levels of a4 and b1 integrins similar to untransfected or
JY9-vector cells, but now also expressed aEb7 (99% aEb7
1,
MFI z80). Both JY9-vector and JY9-aE transfectants also
expressed similar levels of aLb2 (Fig. 4 a).
In the presence of manganese, JY9 cells transfected with
vector alone did not adhere to E-cadherin–Fc coated di-
rectly on microtiter plate wells at any concentration tested.
However, under the washing conditions used, 40% of JY9-
aE cells adhered to 600 ng/well E-cadherin–Fc (Fig. 4 b).
In contrast, both cell lines adhered to ICAM-1–Fc (not
shown) while neither adhered to the control Fc protein hu-
man IgG1 (Fig. 4 b). The higher percent binding observed
for IEL to E-cadherin–Fc when compared with trans-
fected JY9 cells probably reflects the higher surface ex-
Figure 2. SDS-PAGE of pu-
rified recombinant P- and
E-cadherin–Fc fusion pro-
teins. Approximately 2 mg of
P-cadherin–Fc and 1.5 mg of
E-cadherin–Fc protein were
subjected to 7.5% SDS-
PAGE in reducing and non-
reducing conditions and
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pression of aEb7 on IEL (on IEL, mean fluorescence in-
tensity [MFI] z600; on JY9-aE, MFI z80).
The adhesion of JY9-aE cells to E-cadherin–Fc was
blocked from 40% cells bound to ,5% (the level seen for
JY9-vector cells) by mAbs to aEb7 (aE7-2 and BerACT8)
and E-cadherin–Fc (E4.6), but not by blocking mAbs to
aLb2, a4b7, b1, or b2 integrins or to ICAM-1 (Fig. 4 c). In
contrast, the adhesion of JY9-aE cells to ICAM-1–Fc was
blocked by antibodies to aLb2 (TS1/22 and D6.21), b2 inte-
grins (TS1/18), and ICAM-1 (RR1/1), but not by antibod-
ies to aEb7, a4b7, or b1 integrins (data not shown). These
mAb-blocking experiments further confirm that the cell
adhesion measured is mediated by aEb7 binding to E-cad-
herin–Fc, or by aLb2 binding to ICAM-1–Fc.
E-Cadherin–Fc Binds Directly to 125I-labeled aEb7 from 
a Lysate of IEL
To demonstrate that E-cadherin molecules interact di-
rectly with aEb7 molecules, the proteins that bound to E-cad-
Figure 3. Adhesion of cul-
tured intestinal IEL and epi-
thelial cells to E- and P-cad-
herin–Fc. (a) Dose response
of IEL adhesion to E- and
P-cadherin–Fc. Serial dilu-
tions of purified E-cadherin–
Fc, P-cadherin–Fc, and human
IgG1 were immobilized on
microtiter plate wells coated
with polyclonal goat anti–
human IgG antibody and
blocked with BSA. The ad-
hesion of cultured IEL was
determined in the presence
of 1 mM MnCl2, 1 mM
MgCl2, 1 mM CaCl2, 0.1%
BSA, HBS, pH 7.4, as de-
scribed in Materials and
Methods. Adhesion was de-
termined in two indepen-
dent experiments, each in
triplicate, and the results are expressed as the mean percent bound 6 1 SD (n 5 6). (b) Inhibition of adhesion of IEL to E-cadherin–Fc
and ICAM-1–Fc by mAbs. Microtiter plate wells were coated directly with 0.06 mg/well of human E-cadherin–Fc or 0.6 mg/well ICAM-
1–Fc protein, and blocked with BSA. The adhesion of cultured IEL was determined in the presence of 1 mM MnCl2, 1 mM MgCl2, 1 mM
CaCl2, 0.1% BSA, HBS, pH 7.4, and various mAbs. The purified mAbs aE7-2 (anti-aEb7), D6.21 (anti-aLb2), 4B4 (anti-b1), ACT-1
(anti-a4b7), E4.6 (anti–E-cadherin), and RR1/1 (anti–ICAM-1) were used at 10 mg/ml. Ascites fluid containing HML-1 (anti-aEb7), TS1/22
(anti-aLb2), and TS1/18 (anti-b2) were used at a dilution of 1:50. All antibodies were preincubated with IEL for 10 min on ice before ad-
dition to the plate except for RR1/1 and E4.6, which were preincubated in the microtiter plate. All mAbs were mouse IgG1 except
HML-1 (mouse IgG2a). The results are expressed as the mean percent bound 1 1 SD (n 5 5). (c) Dose response of 16E6.A5 cell adhe-
sion to E- and P-cadherin–Fc. Microtiter plates were coated as described for a. Adhesion was determined as described in Materials and
Methods and the results are expressed as the mean percent bound 6 1 SD (n 5 3). The adhesion of 16E6.A5 cells to E-cadherin–Fc is
inhibited by .95% with the anti–E-cadherin mAb HECD-1, but not with the anti–P-cadherin mAb NCC-CAD299. In contrast, the ad-
hesion of 16E6.A5 cells to P-cadherin–Fc is inhibited by 80% with the anti–P-cadherin mAb NCC-CAD299, but not with the anti–
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herin–Fc from a 125I-labeled IEL lysate in the presence of
1 mM MnCl2, 1 mM MgCl2, and 1 mM CaCl2 were ana-
lyzed. Since the fusion protein contains a human IgG1 Fc
region that binds to protein A, a standard immunoadsorp-
tion procedure was used. Proteins of the expected size for
aEb7 (175, 135, and 110 kD) and aLb2 (160 and 100 kD)
were visible on SDS-PAGE in nonreducing conditions af-
ter immunoprecipitation with anti–aEb7 and anti–aLb2
mAbs, respectively (Fig. 5). Remarkably, E-cadherin–Fc
bound to radiolabeled species identical in size and relative
intensity to those seen with the anti–aEb7 mAb (Fig. 5,
compare lanes 1 and 3), but distinct from those seen with
the anti–aLb2 mAb (Fig. 5, compare lanes 3 and 8). In con-
trast, no radiolabeled species were detected binding to the
P-cadherin–Fc or IgG1 proteins. After immunoadsorption
with the ICAM-1–Fc, proteins of the expected size for
aLb2 could be visualized only on overexposed phosphor-
images (not shown). While the same number of cell equiv-
alents were used in each of the human IgG1 containing
protein-binding experiments, z40-fold fewer cell equiva-
lents were required to immunoadsorb an equal amount of
radiolabeled aEb7 with the anti–aEb7 mAb compared with
E-cadherin–Fc (see legend to Fig. 5). This is consistent
with the expected lower affinity of a cell adhesion receptor
interaction compared with that of an antibody–antigen in-
teraction.
Figure 4. Analysis of JY9 cells transfected with aE cDNA. (a) Flow cytometric analysis of the cell surface expression of integrins on JY9
cells transfected with pSRa-neo vector alone (JY9-vector) or with pSRa-neo/aE (JY9-aE). The staining with control mAb P3 is shown
unshaded. Staining with aE7-2 (anti-aEb7), 4B4 (anti-b1), B5G10 (anti-a4), ACT-1 (anti-a4b7), and TS1/22 (anti-aLb2) is shown shaded.
All mAbs were mouse IgG1. (b) Adhesion of transfected JY9 cells to E-cadherin–Fc. Microtiter plate wells were coated directly with se-
rial dilutions of E-cadherin–Fc or human IgG1, and blocked with BSA. The adhesion of JY9-vector and JY9-aE cells was determined in
the presence of 1 mM MnCl2, 1 mM MgCl2, 1 mM CaCl2, 0.1% BSA, HBS, pH 7.4, as described in Materials and Methods. The results
are expressed as the mean percent bound 6 1 SD (n 5 3). (c) Inhibition of adhesion of JY9-aE cells to E-cadherin–Fc by mAbs. Microti-
ter plate wells were coated directly with 0.63 mg/well of E-cadherin–Fc or human IgG1, and blocked with BSA. The adhesion of trans-
fected JY9 cells in the presence of various mAbs was determined as described for IEL in Fig. 3 b. The purified mAbs aE7-2, and
BerACT8 (anti-aEb7), ACT-1 (anti-a4b7), 4B4 (anti-b1), D6.21 (anti-aLb2), E4.6 (anti–E-cadherin), and RR1/1 (anti–ICAM-1) were used
at 10 mg/ml. Ascites fluid containing TS1/18 (anti-b2) was used at a dilution of 1:100. All mAbs were mouse IgG1. The results are expressed
as the mean percent bound 1 1 SD (n 5 4). Adhesion of JY9-vector and JY9-aE cells to human IgG1 in this experiment was ,3%.The Journal of Cell Biology, Volume 140, 1998 204
To further confirm that the proteins bound by anti-aEb7
and the E-cadherin fusion protein were the same, batches
of lysate were precleared with mAbs to aEb7 (aE7-1), aLb2
(TS1/22), or the control mAbs RPC5.4 and P3, before ex-
posure to E-cadherin–Fc (Fig. 5). Prior immunodepletion
with the anti–aEb7 mAb prevented the subsequent binding
of material from the IEL lysate to E-cadherin–Fc. Pre-
clearing with the other mAbs had no such effect. Thus, the
predominant 125I-labeled protein from the IEL cell surface
that interacts with E-cadherin–Fc in these conditions is aEb7.
E-Cadherin–Fc Binds to Soluble Recombinant aEb7
To produce a soluble form of aEb7, stop codons were in-
troduced immediately upstream of the transmembrane
coding regions in the cDNAs encoding the human aE and
b7 proteins (see Fig. 1 b, and Materials and Methods). Su-
pernatant containing 35S-labeled soluble aEb7 was pro-
duced by transient transfection of COS-7 cells followed by
metabolic labeling. Proteins in the supernatant were then
subjected to immunoprecipitation with a panel of anti–
aEb7 antibodies that recognize at least three distinct aE
epitopes (Russell et al., 1994). In the medium from cells
transfected with plasmids encoding truncated aE and b7 in
the sense orientation, all the anti–aEb7 mAbs tested (aE7-1,
aE7-2, aE7-3, HML-1, and BerACT8), but not a control
mAb (TCR-d1), precipitated two major bands of 140 and
105 kD on reducing SDS-PAGE. On nonreducing SDS-
PAGE, two bands of 170 and 100 kD were observed (Fig.
6 and data not shown). These sizes correspond to those ex-
pected for the truncated aE and b7 chains, respectively. No
such proteins were precipitated from the medium of COS-7
cells transfected with constructs containing truncated aE
and b7 cDNAs in the antisense orientation. These results
confirm the secretion of a soluble form of aEb7 that retains
all of the epitopes of cell surface aEb7 that were tested.
We then sought to demonstrate binding of recombinant
soluble aEb7 integrin to the human E-cadherin–Fc fusion.
Both the anti–aEb7 mAb aE7-1 and the E-cadherin–Fc
protein were able to bind proteins of the expected size for
soluble aEb7 (Fig. 6). No detectable soluble aEb7 bound to
the control mAb RPC5.4, or the fusion proteins P-cad-
herin–Fc and ICAM-1–Fc. Furthermore, these proteins
were not bound by E-cadherin–Fc in medium from COS-7
Figure 5. Binding of aEb7 from an IEL lysate to E-cadherin–Fc.
Cultured intestinal IEL were surface labeled with 125I and solubi-
lized as described in the text. Batches of lysate were subjected to
immunoadsorption with mAbs or human IgG1 Fc containing pro-
teins in the presence of 1 mM MnCl2, 1 mM MgCl2, 1 mM CaCl2.
Samples were resolved by 7.5% SDS-PAGE in nonreducing con-
ditions, and visualized by autoradiography. The precipitations
with  aE7-1 and RPC5.4 mAbs (both mouse IgG2a) represent the
material obtained using 0.1 ml ascites from 7 3 104 cell equiva-
lents, for TS1/22 and P3 mAbs (both mouse IgG1, with rabbit
anti–mouse IgG) using 0.5 ml ascites from 7 3 105 cell equiva-
lents, and for E-cadherin–Fc, P-cadherin–Fc, ICAM-1–Fc and
human IgG1 using 5 mg fusion protein from 3 3 106 cell equiva-
lents. For the preclearing experiments, batches of 1.5 3 106 cell
equivalents were preabsorbed with the stated antibodies and pro-
tein A–Sepharose, before immunoadsorption with 2.5 mg E-cad-
herin–Fc.
Figure 6. Direct binding of soluble recombinant aEb7 to E-cad-
herin–Fc. COS-7 cells transiently transfected with either aE and
b7 constructs in the sense or in the antisense orientation were
metabolically labeled with 35S amino acids as described in the
text. The medium was then made 1 mM with respect to MnCl2
and subjected to immunoadsorption with antibodies or Fc-fusion
proteins. Samples were resolved on 7.5% SDS-PAGE in nonre-
ducing conditions, and visualized by autoradiography. The pre-
cipitations with aE7-1 and RPC5.4 mAbs (both mouse IgG2a)
represent the material obtained using 0.25 ml medium and 0.5 ml
ascites, and for E-cadherin–Fc, P-cadherin–Fc, and ICAM-1–Fc,
using 1.0 ml medium and 5 mg fusion protein. Aggregated mate-
rial is present in the both control and test E-cadherin–Fc adsorp-
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cells transfected with the antisense aE and b7 constructs
(Fig. 6). Thus, E-cadherin–Fc interacts with soluble aEb7
in the absence of other cellular proteins that are present in
the IEL lysate used previously.
The Avidity of Cell Surface aEb7 Is Regulated
Although the avidity of many integrins is regulated from
within the cell, similar regulation of aEb7 has not previ-
ously been reported. Furthermore, the structure of the aE
chain is unique among integrins due to the presence of an
extra domain in the extracellular region, membrane distal
of the A domain, that is cleaved in the mature protein (the
“X” domain, see Fig. 1 b; Shaw et al., 1994). This raises the
possibility that regulation of the avidity of aEb7 due to
conformational changes could be different from other in-
tegrins. Therefore, studies were performed to investigate
the regulation of aEb7 avidity on JY9-aE cells and IEL, and
to compare it to the well studied aLb2 integrin.
JY9 cells transfected with aE adhered poorly to E-cad-
herin–Fc in the presence of 1 mM MgCl2 and 1 mM CaCl2
in the absence of manganese. The addition of 1 mM man-
ganese caused a 12-fold or greater rise in the adhesion of
JY9-aE cells to E-cadherin–Fc. PMA stimulation of JY9-aE
also caused a sevenfold increase in binding to E-cadherin–Fc
(Fig. 7 a). Adhesion of JY9-aE cells to ICAM-1–Fc was
also enhanced by manganese or PMA, suggesting that
both aEb7 and aLb2 can be activated by similar means.
Relative to the effect of manganese, PMA was better able
to stimulate adhesion of JY9-aE to ICAM-1–Fc than to
E-cadherin–Fc. The reason for this difference is unclear,
but valid comparisons are difficult since aLb2 is expressed
at a higher level than aEb7 on JY9-aE cells (Fig. 3 a).
In contrast to JY9 transfectants, .90% of IEL adhered
to E-cadherin–Fc in 1 mM MgCl2 and 1 mM CaCl2 and the
addition of manganese or PMA had little enhancing effect
on adhesion (not shown). Thus IEL, which are maintained
in culture in the presence of IL-2 with periodic PHA-stim-
ulation, have constitutively active aEb7 in these conditions.
To study regulation of aEb7 on IEL, we carried out assays
in 0.05 mM MgCl2 and 1 mM CaCl2. In these conditions of
limiting MgCl2, just under 40% of IEL adhere to E-cad-
herin–Fc (Fig. 7 b). The addition of manganese or PMA
causes an almost twofold increase in the percentage of
IEL adhering to E-cadherin–Fc. Moreover, cross-linking
of the TCR complex with a mouse anti–CD3 mAb, fol-
lowed by anti–mouse immunoglobulin polyclonal anti-
body, also causes a significant increase in IEL adhesion to
E-cadherin–Fc (P , 0.0001, by Welch’s alternate t test, see
Fig. 7 b). Similar treatment of IEL with antibodies to
CD8a or MHC class I had no such effect. Cross-linking of
the TCR on IEL also increases the avidity of aLb2 for
ICAM-1, and of b1-integrins for fibronectin (data not
shown), as has been reported for other T cells (Dustin and
Springer, 1989; Shimizu et al., 1990; van Kooyk et al., 1989).
It is known that calcium is required for the rigidification
of the structure of E-cadherin (Nagar et al., 1996; Pokutta
et al., 1994) and for E-cadherin–mediated homotypic cell
to cell adhesion (Hyafil et al., 1981; Yoshida and Takeichi,
1982). However, in the presence of magnesium, even when
calcium has been depleted with EGTA, both JY9-aE cells
(Fig. 7 a) and IEL (not shown) adhere to E-cadherin–Fc.
Thus, the heterophilic interaction of E-cadherin appears
to be independent of calcium, at least in this system. It is
unlikely that this is due to restriction of conformational
changes within plate-bound E-cadherin–Fc, since similar
results were found whether the fusion protein was immo-
bilized directly on plastic or through its Fc region on anti-
immunoglobulin antibodies (not shown). In contrast, the
Figure 7. Regulation of JY9-aE cell and IEL adhesion to E-cad-
herin–Fc and ICAM-1–Fc. (a) The adhesion of JY9-aE cells to 0.6
mg/well directly coated E-cadherin–Fc and ICAM-1–Fc under
various conditions. EDTA (10 mM) was present during coating
and blocking of the microtiter plates, and was washed out with
HBS before adding cells. The adhesion buffer was 0.1% BSA/
HBS, pH 7.4, containing divalent cations and 50 ng/ml PMA or 1 mM
EGTA where appropriate. The results are expressed as mean
percent adhesion 1 1 SD (n 5 6 for adhesion to E-cadherin–Fc, n
5 3 for adhesion to ICAM-1–Fc). The percent adhesion to hu-
man IgG1 under the each condition was subtracted from the re-
sults (,5% in each case). (b) The adhesion of IEL to 0.1 mg/well
E-cadherin–Fc under various conditions. The adhesion buffer
was 0.05 mM MgCl2, 1 mM CaCl2, 0.1% BSA, HBS, pH 7.4, un-
less otherwise stated. Ascites containing antibodies (all mouse
IgG2a) to MHC I (W6/32), CD8a (OKT8), nonbinding control
(RPC5.4), and CD3 (SPVT3b) were used at a dilution of 1:100
and cross-linked with 10 mg/ml rabbit anti–mouse IgG polyclonal
antibody. Where appropriate, 1 mM MnCl2 or 50 ng/ml PMA was
also included. The results are expressed as mean percent adhe-
sion 1 1 SD (n 5 6, except for experiments with OKT8 and
RPC5.4 where n 5 3). In both a and b, P values calculated by
Welch’s alternate t test compared with the Mg/Ca alone are as
follows: ***P , 0.0001, **P , 0.001, *P , 0.01. In addition, for
adhesion to E-cadherin–Fc, P values by the Mann-Whitney test
compared with Mg/Ca alone are: ***P 5 0.002, **P , 0.005 (see
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adhesion of E-cadherin–expressing 16E6.A5 epithelial
cells to E-cadherin–Fc is dependent on calcium (not
shown). Also, since mouse E-cadherin does not have ap-
preciable affinity for magnesium (Hyafil et al., 1981), and
magnesium cannot support homophilic adhesion to E-cad-
herin–Fc (not shown), it is unlikely that magnesium substi-
tutes for calcium in the cadherin structure. The results also
suggest that calcium is not required for the function of
aEb7 integrin. This is also the case for aLb2 binding to
ICAM-1 (Fig. 7 a; Shimizu and Mobley, 1993; Stewart et
al., 1996).
In summary, aEb7, like aLb2, can exist in both high and
low avidity states on the cell surface. In common with
aLb2–mediated adhesion to ICAM-1, treatment of cells ex-
pressing aEb7 in a low avidity state with manganese, with
PMA, with anti–CD3 antibodies, or by removing calcium
and elevating magnesium, leads to increased adhesion to
E-cadherin–Fc.
The Direct Binding of E-Cadherin–Fc to Solubilized 
aEb7 Is Modulated by Divalent Cations
We wished to determine if the effects of divalent cations
on cell adhesion to E-cadherin–Fc were due to a direct in-
fluence on the binding of aEb7 molecules to E-cadherin–
Fc molecules. The binding of E-cadherin–Fc to 125I-labeled
aEb7 in an IEL lysate was analyzed by immunoadsorption
as described in Fig. 5, but in the presence of various con-
centrations of divalent cations (Fig. 8). No binding of
E-cadherin–Fc to aEb7 was detected in the presence of 5 mM
EDTA, confirming the cation dependency of the interac-
tion (Fig. 8 b). Binding of E-cadherin–Fc to aEb7 was clear
in the presence of 1 mM MgCl2 and 1 mM CaCl2, but was
increased eightfold by the addition of 1 mM MnCl2 (Fig. 8
b). Approximately equal quantities of aEb7 were immu-
noadsorbed by the anti–aEb7 mAb aE7-1 in all conditions,
confirming that the differences seen in binding to the
E-cadherin–Fc fusion protein were not due to dissociation
or degradation of the aEb7 chains (Fig. 8 a). Furthermore,
since cadherins are known to be protease sensitive in the
absence of calcium, we confirmed that an equal quantity of
E-cadherin–Fc protein was present in each condition by
Coomassie Blue staining of the immunoadsorbed material
(Fig. 8 b, ii).
Thus, the cation dependency of aEb7-mediated cell ad-
hesion to E-cadherin–Fc is paralleled by the cation depen-
dency of aEb7 binding directly to E-cadherin–Fc. Also, the
association of aE with b7 chains is not dependent on cal-
cium or magnesium, as found for mouse aEb7 (Kilshaw
and Murant, 1991), but in contrast to mouse a4b7, an inte-
grin that requires calcium for heterodimer formation in
similar experiments (Holzmann et al., 1989).
Discussion
Here, we demonstrate that an E-cadherin fusion protein
binds directly both to aEb7 from solubilized intraepithelial
lymphocytes, and to a soluble recombinant form of aEb7.
Furthermore, purified E-cadherin fusion protein can serve
as a potent substrate for cell adhesion through the aEb7 in-
tegrin. Thus, although E-cadherin is classically thought to
be a homophilic adhesion molecule and is unlike known
integrin ligands, it is a direct counter receptor for the aEb7
integrin.
We found that aEb7 exhibits selectivity in binding to
cadherins. The adhesion of IEL cells to P-cadherin–Fc re-
quires .100-fold more fusion protein than adhesion to
E-cadherin–Fc. In both cases the adhesion is dependent on
aEb7, since it is abolished by antibodies to aEb7. Thus, al-
though human epithelial cells express both E- and P-cad-
herin, it is likely that E-cadherin is the primary epithelial
receptor for aEb7 in vivo. The idea that aEb7 is selective in
binding cadherins is consistent with the proposed role of
aEb7 in tissue-specific leukocyte adhesion, and with the
finding that IEL do not adhere to all cadherin-expressing
cells. For example, IEL do not adhere to endothelial cells
that possess VE-cadherin (Cepek et al., 1994).
Figure 8. Direct binding of aEb7 to E-cadherin–Fc is modulated
by divalent cations. (a) Immunoadsorption of aEb7 by an anti–
aEb7 mAb is unaffected by divalent cations. Batches of 125I-labeled
IEL lysate were subjected to immunoadsorption with the aE7-1
mAb in the presence of divalent cations or EDTA as shown.
Samples were resolved by 7.5% SDS-PAGE in nonreducing con-
ditions, and aEb7 was visualized by autoradiography. (b) Immu-
noadsorption of aEb7 by E-cadherin–Fc is modulated by divalent
cations. (i) In duplicate, batches of 125I-labeled IEL lysate were
subjected to immunoadsorption with E-cadherin–Fc in the condi-
tions shown in a. (ii) The presence of an equal quantity of E-cad-
herin–Fc in the immunoadsorbed material was confirmed by
7.5% SDS-PAGE in reducing conditions and Coomassie blue
staining. (iii) Quantitation of aEb7 bound to E-cadherin–Fc in
each condition. Phosphorimage quantitation of aEb7 was based
upon the 175- and 135-kD bands corresponding to the aE-chain
(Shaw et al., 1994). The averages of duplicates for each band
were combined. The precipitations with aE7-1 represent the ma-
terial obtained using 0.05-ml ascites from 6 3 104 cell equivalents
and for E-cadherin–Fc using 5 mg fusion protein from 2 3 106 cell
equivalents.Higgins et al. Direct Interaction of aEb7 Integrin and E-Cadherin 207
Regulation of aEb7 avidity for its counter receptor has
not previously been reported. An increase in IEL adhe-
sion to epithelial cells in the presence of manganese has
been observed (Cepek et al., 1993; Karecla et al., 1995).
However, it is not clear that this change is due to regula-
tion of aEb7 binding to E-cadherin since other receptors,
including aLb2 and ICAM-1, are involved in this complex
cell to cell interaction (Cepek et al., 1993; Roberts et al.,
1993). Here, the adhesion of cells expressing both aEb7
and aLb2 to purified E-cadherin–Fc or ICAM-1–Fc al-
lowed us to compare the regulation of aEb7 avidity with
that of aLb2 in a system in which only a single integrin
counter receptor was available in each case. The aLb2 inte-
grin on freshly isolated PBL has low avidity for immobi-
lized ICAM-1 in the presence of 1 mM MgCl2 and 1 mM
CaCl2. However, in the presence of manganese ions PBL
adhere strongly to purified ICAM-1 (Dransfield et al.,
1992). Changes in the concentrations and presence of diva-
lent cations are thought to have a direct effect on the con-
formation of the integrin at the cell surface, leading to in-
creased ligand binding through an increase in the affinity
of the integrin and/or changes in clustering of the integrin
in the membrane. In addition, signaling from inside the
cell can lead to increased integrin avidity. For example,
PMA stimulation of resting PBL leads to increased adhe-
sion to ICAM-1 through aLb2. This type of regulation may
involve changes in integrin clustering on the cell surface
due to alterations in integrin association with the cytoskel-
eton (Lub et al., 1995, 1997; Stewart et al., 1996). In con-
trast to resting PBL, aLb2 on a proportion of IL-2/PHA-
activated PBL has high avidity for ICAM-1 (Lub et al.,
1997). Furthermore, the avidity state of integrins trans-
fected into different cell types can vary. For example, aLb2
expressed on K562 cells is in a constitutively inactive state,
while  aLb2 expressed on L cells is constitutively active
(Lub et al., 1995).
We find that in 1 mM MgCl2 and 1 mM CaCl2, aE-trans-
fected JY9 cells exhibit poor adhesion to both E-cadherin–Fc
and ICAM-1–Fc. Thus, on these cells, both aEb7 and aLb2
exist in a low avidity state. However, these cells can be in-
duced to adhere to both integrin ligands by the addition of
1 mM MnCl2. Since parallel changes in the direct binding
of solubilized aEb7 to E-cadherin–Fc were also observed,
it is likely that this difference in cell adhesiveness is due to
a direct effect of manganese on the conformation of the
aEb7 integrin. Thus, changes in extracellular cations can
regulate the affinity of aEb7 for its ligand. In contrast, cul-
tured IEL, which are maintained in IL-2 with periodic
stimulation with PHA and feeder cells, adhere avidly to
both E-cadherin–Fc and ICAM-1–Fc in 1 mM MgCl2 and
1 mM CaCl2 even in the absence of manganese. Both aEb7
and aLb2 on IEL appear to be maintained in a constitu-
tively active state, like aLb2 on a proportion of IL-2/PHA-
stimulated peripheral blood T cells.
We also show that signaling from inside the cell is able
to increase the avidity of aEb7. The addition of the phorbol
ester, PMA, which acts intracellularly to upregulate pro-
tein kinase C, leads to increased adhesion of aE-trans-
fected JY9 cells to E-cadherin–Fc or ICAM-1–Fc. In the
presence of a suboptimal concentration of magnesium,
PMA also enhanced IEL adhesion to E-cadherin–Fc. The
physiological triggers for such changes in lymphocyte inte-
grin avidity in vivo remain unclear. In vitro, chemokines
such as MCP-1, MIP-1b, and RANTES can activate lym-
phocyte integrins (Campbell et al., 1996; Carr et al., 1996;
Lloyd et al., 1996), and cross-linking of components of the
T cell receptor can boost the adhesion of resting PBL to
ICAM-1 through aLb2 (Dustin and Springer, 1989; van
Kooyk et al., 1989) or to fibronectin and laminin through
b1-integrins (Shimizu et al., 1990). Here, we report that
antibody cross-linking of cell surface CD3 is similarly able
to increase IEL adhesion to E-cadherin–Fc, while cross-
linking of MHC class I or CD8 receptors had no such ef-
fect. Thus, recognition by an IEL of an antigen presented
by an epithelial cell or a professional antigen-presenting
cell expressing E-cadherin (such as a Langerhans cell;
Tang et al., 1993) could trigger increased adhesion to that
cell through an upregulation of aEb7 avidity. This interac-
tion may also provide costimulation to the T cell, since
anti–aEb7 antibodies, in common with anti–aLb2 antibod-
ies, are known to increase T cell proliferation in the pres-
ence of suboptimal anti-CD3 (Russell et al., 1994; Sarnacki
et al., 1992; Wacholtz et al., 1989), and ICAM-1 on an anti-
gen-presenting cell can costimulate through aLb2 (Dubey
et al., 1995). Such events may be important in arresting
lymphocytes within the epithelium when a specific antigen
is recognized. In addition, since IEL contact more than
one cell when resident within the epithelium, localized up-
regulation of aEb7 avidity within an IEL could aid in po-
larizing lymphocyte interactions toward the relevant anti-
gen-presenting cell.
X-ray crystallography and NMR studies have recently
revealed that cadherin modules adopt a tertiary structure
rather like immunoglobulin domains (Overduin et al.,
1995; Shapiro et al., 1995; Nagar et al., 1996). Thus E-cad-
herin has a structure resembling that of the known cellular
integrin ligands and can now be placed within the family
of immunoglobulin-like, integrin-binding proteins. E-cad-
herin may share another feature of well-defined integrin
ligands; the presence of a solvent-exposed acidic residue
vital for integrin binding (Bergelson and Hemler, 1995).
Mutation of an aspartate or glutamate residue in the CD-
loop region in domain 1 of the immunoglobulin superfam-
ily integrin ligands VCAM-1 (Osborn et al., 1994; Renz et
al., 1994; Vonderheide et al., 1994; Jones et al., 1995; Wang
et al., 1995), ICAM-1, (Staunton et al., 1990; Holness et al.,
1995), and MadCAM-1 (Briskin et al., 1996; Viney et al.,
1996) abolishes integrin binding. The tenth immunoglobu-
lin-like FN III repeat of fibronectin also has an acidic resi-
due within the RGD sequence on the FG-loop that is in-
volved in integrin binding (Main et al., 1992). In mouse
E-cadherin, the BC loop of domain 1 contains a glutamate
residue required for adhesion of aEb7-expressing lympho-
cytes to E-cadherin–transfected L cells (Karecla et al.,
1996). Since this residue is conserved in human E-cadherin
and we demonstrate that E-cadherin is a direct counter re-
ceptor for aEb7, it is likely that this amino acid contributes
directly to the aEb7-binding site on E-cadherin, in a man-
ner similar to that proposed for other integrin ligands. It is
interesting to note that while three different families of
immunoglobulin-like structures with exposed acidic amino
acids serve as integrin ligands, the face of the module in-
volved appears to be different in each case. It is also in-
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dimeric on the cell surface (Miller et al., 1995; Reilly et al.,
1995; Nagar et al., 1996), and that both are ligands of inte-
grins that contain an A domain in the a chain (aEb7 and
aLb2, respectively). Since it has been proposed that inte-
grin b-chains also contain a ligand-binding A domain (Lee
et al., 1995; Puzon-McLaughlin and Takada, 1996), it is
possible that aEb7 and aLb2 actually possess two A do-
mains each. As suggested for aLb2 binding to ICAM-1
(Miller et al., 1995), it is tempting to speculate that the
binding of dimeric E-cadherin by aEb7 could involve both
these domains.
Although E-cadherin is a calcium-binding molecule, we
find that E-cadherin–Fc binding to aEb7 is independent of
calcium. It seems that calcium is not directly involved in
maintenance of the aEb7 binding site on E-cadherin. Stud-
ies with recombinant soluble forms of mouse E-cadherin
and Xenopus C-cadherin suggest that homophilic cadherin
interactions do require the presence of calcium (Brieher et
al., 1996; Tomschy et al., 1996). Interestingly, in their
NMR studies of the first module of mouse E-cadherin,
Overduin et al. (1995) find that the addition of calcium
leads to a large shift in the orientation of histidine-79
within the HAV motif implicated in homophilic E-cad-
herin interaction (Blaschuk et al., 1990; Shapiro et al.,
1995). In contrast, no such shift is found in any of the resi-
dues in or around the BC-loop implicated in aEb7 interac-
tion (Overduin et al., 1995). Thus it is possible that
changes in extracellular calcium levels (for review see
Maurer et al., 1996) would differentially regulate E-cad-
herin binding to aEb7 versus other E-cadherin molecules.
However, since calcium is required to rigidify and extend
E-cadherin (Pokutta et al., 1994; Nagar et al., 1996) and to
protect it from proteolysis (Hyafil et al., 1981; Yoshida and
Takeichi, 1982), the lack of calcium dependence for aEb7-
mediated adhesion to the E-cadherin–Fc fusion protein
may not hold true on the cell surface.
Although the role of aEb7 binding to E-cadherin in vivo
has yet to be established, the direct, specific, and regulated
binding of aEb7-expressing cells and of aEb7 itself to the
E-cadherin fusion protein very strongly suggests a physio-
logical function for this interaction. Although there is an
increase in the number of b7-integrin positive iIEL in chi-
meric mice with a defect in intestinal E-cadherin expression
(Hermiston and Gordon, 1995), this is perhaps not surpris-
ing since the observed disruption of the epithelial layer
and accompanying infectious and inflammatory response
is likely to result in the attraction of many leukocytes into
the intestine. In contrast, recently developed aE knockout
mice have reduced numbers of intraepithelial IEL (Parker,
C.M., unpublished results).
The role in vivo of the low but detectable aEb7-medi-
ated adhesion of IEL to human P-cadherin is more diffi-
cult to assess. The relative abundance of E- and P-cad-
herin on epithelial cells depends upon the state of cell
differentiation (Hirai et al., 1989a,b), but this may not be
the sole determinant of aEb7-mediated interactions. On a
single cell type, cadherins can display differential associa-
tion with the cytoskeleton and thus exist in distinct pools
on the cell surface (Salomon et al., 1992), and E- and
P-cadherin are found in separate complexes on A431 cells
(Johnson et al., 1993). Cell adhesion through homophilic
cadherin–cadherin interactions requires their association
with the cytoskeleton through intracellular catenins (Na-
gafuchi and Takeichi, 1988). However, while E-cadherin
lacking its cytoplasmic tail is unable to associate with the
catenins and cannot support strong homophilic adhesion,
it is able to support adhesion of lymphocytes expressing
aEb7 (Karecla et al., 1996). So, since different pools of cad-
herins may differ in their availability for interaction with
different counter receptors, it is difficult to predict whether
or not a high local concentration of a distinct population of
P-cadherin on the cell surface could contribute to aEb7-
mediated adhesion.
Like human, mouse, canine, and Xenopus E-cadherin,
human P-cadherin possesses an acidic residue at the tip of
the BC loop in the first cadherin module (Shimoyama et
al., 1989b). Thus human E- and P-cadherin may share a
similar mode of binding to aEb7. In contrast, mouse P-cad-
herin does not possess an acidic residue at this position
(Nose et al., 1987), and it has been reported that murine
lymphocytes expressing aEb7 do not adhere to L cells
transfected with mouse P-cadherin (Karecla et al., 1996).
Although this cell to cell adhesion assay is likely to be less
sensitive than the cell to fusion protein assay used here,
these findings further complicate the question of the po-
tential importance of aEb7 binding to P-cadherin. It is pos-
sible that in some respects the function of P-cadherin may
differ in the two species, and this may be reflected in the
different expression pattern of P-cadherin in human and
mouse (Shimoyama et al., 1989a,b).
Recently, a second direct heterophilic noncadherin
ligand of a cadherin has been identified. The Listeria sur-
face protein internalin binds to E-cadherin and invasion of
cells expressing E-cadherin by Listeria in vitro is inhibited
by anti–E-cadherin antibodies (Mengaud et al., 1996). To-
gether with studies suggesting that different cadherins can
bind to each other (for example N- and R-cadherin)
(Takeichi, 1995), it is now clear that the biology of cad-
herin function is not limited to homophilic interactions,
and is more complex than previously imagined.
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